PD-1 antibody
Showing 1 - 25 of >10,000
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)
Not yet recruiting
- PD-1 Antibody
- +3 more
- L-DEP and PD-1 antibody
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 8, 2023
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite
Completed
- Metastatic Colorectal Adenocarcinoma
- regorafenib plus anti-PD-1 antibodies
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 4, 2023
Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:
Not yet recruiting
- Hepatocellular Carcinoma Non-resectable
- transarterial therapies
- (no location specified)
Nov 27, 2022
Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)
Not yet recruiting
- Neoadjuvant Chemotherapy
- +3 more
- neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
- (no location specified)
Sep 21, 2022
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- HST-1011
- Cemiplimab
- (no location specified)
Dec 14, 2022
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +4 more
- KRAS-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin
Recruiting
- Gastric Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Oct 22, 2023
Locally Advanced Unresectable or Metastatic Esophageal Cancer Trial (Futibatinib, Pembrolizumab, Cisplatin)
Not yet recruiting
- Locally Advanced Unresectable or Metastatic Esophageal Cancer
- Futibatinib
- +6 more
- (no location specified)
Jul 6, 2023
Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)
Recruiting
- Solid Tumor, Adult
- +6 more
- TP53-EphA-2-CAR-DC
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022
Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)
Not yet recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
- Camrelizumab
- +4 more
- (no location specified)
Feb 17, 2023
Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))
Recruiting
- Cholangiocarcinoma, Intrahepatic
- Capecitabine
- PD-1 Antibody(Tislelizumab)
-
Shanghai, ChinaLulu@Huashan.Org.Cn
Aug 16, 2022
Immune Function and PD-1 Antibody Therapy Efficacy Predictors on
Recruiting
- Secondary Hemophagocytic Lymphohistiocytosis
- Chronic Active Epstein-Barr Virus Infection
- No intervention
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
May 2, 2023
Esophageal Squamous Cell Carcinoma Abdominal Stage 0 Trial in Guangzhou (PD-1 Inhibitors, Irinotecan, Capecitabine tablets)
Recruiting
- Esophageal Squamous Cell Carcinoma Abdominal Stage 0
- PD-1 Inhibitors
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 20, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)
Not yet recruiting
- Colorectal Cancer
- Serplulimab + FOLFOXIRI
- Radiation therapy
- (no location specified)
Oct 24, 2023
NSCLC Trial in China (PD-1 Antibody, BACE)
Recruiting
- NSCLC
- PD-1 Antibody
- BACE
-
Guiyang, Guizhou, China
- +7 more
Nov 8, 2022
Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency Trial in Guangzhou (drug, radiation, procedure, other)
Active, not recruiting
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
- Oxaliplatin
- +5 more
-
Guangzhou, Guangdong, ChinaMedical Oncology,Sun Yat-sen University Cancer Center
Jan 29, 2023
Sintilimab in Combination With Chemoradiotherapy in High-risk
Recruiting
- Nasopharyngeal Carcinoma
- Sintilimab
- Sintilimab (PD-1 Antibody)
-
Nanning, Guangxi, ChinaGuangxi Medical University Cancer Hospital
Jan 29, 2023
Hepatocellular Carcinoma Trial in Shanghai (PD-1 and Lenvatinib Plus TACE)
Recruiting
- Hepatocellular Carcinoma
- PD-1 and Lenvatinib Plus TACE
-
Shanghai, Shanghai, ChinaHuashan hospital
Aug 16, 2022
Perihilar Cholangiocarcinoma Trial in Guangzhou (PD-1antibody plus GEMOX)
Not yet recruiting
- Perihilar Cholangiocarcinoma
- PD-1antibody plus GEMOX
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022